BMC MED:LDL-C达标就不会中风?错!没有进行调脂治疗仍可能有高的卒中风险!

2022-07-10 MedSci原创 MedSci原创

有证据表明,低密度脂蛋白胆固醇(LDL-C)浓度很低的个体发生中风的风险仍然很高。

有证据表明,低密度脂蛋白胆固醇(LDL-C)浓度很低的个体发生中风的风险仍然很高。来自我国的学者试图利用机器学习方法中的生存条件推理树,对LDL-C浓度<70 mg/dL(3.85mmol/L)的中国参与者的中风预测性风险因素进行优先排序。结果发表在BMC MEDICINE杂志上。

训练数据集包括9327名LDL-C浓度<70 mg/dL、无心血管疾病且未使用调脂药物的开滦一期研究人员(N = 101510)。在第二个中国队列中检查了该算法的有效性,该队列包括开滦二期研究中1753名LDL-C浓度<70 mg/dL的参与者(N = 35856)。

结果显示,在平均8.5-9.0年的随访期间,研究人员在训练数据集中发现388例缺血性卒中和145例出血性卒中,在验证数据集中发现20例缺血性卒中和8例出血性卒中。在15个检查的预测因子中,血压控制不佳和LDL-C浓度很低(≤40 mg/dL)是缺血性卒中风险和出血性卒中风险的最高层次预测因子。

相对于最低风险组(存在这些因素的0-1)的患者,存在2-3个上述风险因素为特征的群体与较高的缺血性卒中风险有关(训练集HR=7.03;95%CI 5.01-9.85;验证集HR=4.68,95%CI 1. 58-13.9)和出血性卒中(训练集HR=3.94,95%CI 2.54-6.11;验证集HR=4.73,95%CI 0.81-27.6)。累积平均LDL-C浓度与卒中风险之间存在线性关系。调整年龄、高血压状态和其他协变量后,与LDL-C浓度为55-70 mg/dL相比,LDL-C浓度≤40 mg/dL与缺血性卒中(HR= 2.07, 95%CI 1.53, 2.80)和出血性卒中(HR= 2.70, 95%CI 1.70, 4.30)风险增加明显相关。

综上,低密度脂蛋白胆固醇浓度极低的人,如果以前没有进行调脂治疗,仍可能有高的卒中风险。

 

参考文献:

The risk of ischemic stroke and hemorrhagic stroke in Chinese adults with low-density lipoprotein cholesterol concentrations < 70 mg/dL. BMC Med 19, 142 (2021).

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1975209, encodeId=7f1b19e5209f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Sep 17 12:35:16 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281402, encodeId=050e1281402d9, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422618, encodeId=2560142261879, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611651, encodeId=8b85161165182, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623623, encodeId=0f67162362322, content=<a href='/topic/show?id=16fc9204535' target=_blank style='color:#2F92EE;'>#调脂治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92045, encryptionId=16fc9204535, topicName=调脂治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc220567061, createdName=muzishouyi, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626408, encodeId=62ae1626408f2, content=<a href='/topic/show?id=d71f9204488' target=_blank style='color:#2F92EE;'>#调脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92044, encryptionId=d71f9204488, topicName=调脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fe521012482, createdName=gostraight, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-09-17 ms3025846204744509

    #BMC#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1975209, encodeId=7f1b19e5209f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Sep 17 12:35:16 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281402, encodeId=050e1281402d9, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422618, encodeId=2560142261879, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611651, encodeId=8b85161165182, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623623, encodeId=0f67162362322, content=<a href='/topic/show?id=16fc9204535' target=_blank style='color:#2F92EE;'>#调脂治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92045, encryptionId=16fc9204535, topicName=调脂治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc220567061, createdName=muzishouyi, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626408, encodeId=62ae1626408f2, content=<a href='/topic/show?id=d71f9204488' target=_blank style='color:#2F92EE;'>#调脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92044, encryptionId=d71f9204488, topicName=调脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fe521012482, createdName=gostraight, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-07-11 wmr111
  3. [GetPortalCommentsPageByObjectIdResponse(id=1975209, encodeId=7f1b19e5209f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Sep 17 12:35:16 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281402, encodeId=050e1281402d9, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422618, encodeId=2560142261879, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611651, encodeId=8b85161165182, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623623, encodeId=0f67162362322, content=<a href='/topic/show?id=16fc9204535' target=_blank style='color:#2F92EE;'>#调脂治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92045, encryptionId=16fc9204535, topicName=调脂治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc220567061, createdName=muzishouyi, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626408, encodeId=62ae1626408f2, content=<a href='/topic/show?id=d71f9204488' target=_blank style='color:#2F92EE;'>#调脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92044, encryptionId=d71f9204488, topicName=调脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fe521012482, createdName=gostraight, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-07-11 zhwj

    #LDL#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1975209, encodeId=7f1b19e5209f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Sep 17 12:35:16 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281402, encodeId=050e1281402d9, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422618, encodeId=2560142261879, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611651, encodeId=8b85161165182, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623623, encodeId=0f67162362322, content=<a href='/topic/show?id=16fc9204535' target=_blank style='color:#2F92EE;'>#调脂治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92045, encryptionId=16fc9204535, topicName=调脂治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc220567061, createdName=muzishouyi, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626408, encodeId=62ae1626408f2, content=<a href='/topic/show?id=d71f9204488' target=_blank style='color:#2F92EE;'>#调脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92044, encryptionId=d71f9204488, topicName=调脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fe521012482, createdName=gostraight, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-07-11 ms3994565386320060

    #Med#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1975209, encodeId=7f1b19e5209f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Sep 17 12:35:16 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281402, encodeId=050e1281402d9, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422618, encodeId=2560142261879, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611651, encodeId=8b85161165182, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623623, encodeId=0f67162362322, content=<a href='/topic/show?id=16fc9204535' target=_blank style='color:#2F92EE;'>#调脂治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92045, encryptionId=16fc9204535, topicName=调脂治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc220567061, createdName=muzishouyi, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626408, encodeId=62ae1626408f2, content=<a href='/topic/show?id=d71f9204488' target=_blank style='color:#2F92EE;'>#调脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92044, encryptionId=d71f9204488, topicName=调脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fe521012482, createdName=gostraight, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-07-11 muzishouyi
  6. [GetPortalCommentsPageByObjectIdResponse(id=1975209, encodeId=7f1b19e5209f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Sep 17 12:35:16 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281402, encodeId=050e1281402d9, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422618, encodeId=2560142261879, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611651, encodeId=8b85161165182, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623623, encodeId=0f67162362322, content=<a href='/topic/show?id=16fc9204535' target=_blank style='color:#2F92EE;'>#调脂治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92045, encryptionId=16fc9204535, topicName=调脂治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc220567061, createdName=muzishouyi, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626408, encodeId=62ae1626408f2, content=<a href='/topic/show?id=d71f9204488' target=_blank style='color:#2F92EE;'>#调脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92044, encryptionId=d71f9204488, topicName=调脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fe521012482, createdName=gostraight, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-07-11 gostraight

    #调脂#

    0

相关资讯

Stroke:如何对短暂性脑缺血发作或小中风后进行多模式预防

强化护理项目组的患者在1年后体能和mRS的结果略好,但其他以患者为中心的结果都没有明显改善。

降压、降脂,防国人心血管病意义最大!周脉耕、胡国清等预测研究

血压控制对缺血性心脏病和出血性脑卒中死亡的贡献最大,分别可减少67.73和39.11万例的死亡。

Stroke:为第二次攻击做准备——关于中风后网络恢复能力的病变模拟研究

在这个经过高度筛选的病变局限于初级运动皮层的患者群中,大脑网络重新配置,以增加对未来打击事件的复原力。

JAMA:无症状严重颈动脉狭窄患者的缺血性中风发生率有多高?

无症状严重颈动脉狭窄患者队列中,没有进行手术干预,同侧颈动脉相关急性缺血性卒中的估计比率在5年内为4.7%。

stroke:≥85岁急性缺血性脑卒中患者血管内治疗后的功能结果

与保守治疗相比,≥85岁的独立病前功能患者在接受EVT治疗时更多地获得良好的功能结果,死亡率也更低。

拓展阅读

CSA&TISC 2026 | 降至多少才安全?——缺血性卒中患者极低LDL-C水平的安全性再探讨

米东华教授指出,血脂全程管理过程中,一定要平衡获益和出血风险,海博麦布全部数据都来自中国人群,其临床参考价值更高,非常适合国内卒中患者的使用。

ACC.26丨周欣教授:心血管风险精准管理的前沿进展——血压干预与LDL-C靶目标值优化的最新临床证据

POCKETIN特邀天津医科大学总医院杨清教授团队深入剖析这些可能改变临床实践的重要证据。

2025年心血管领域关键进展:血脂异常的十大研究

本文总结了2025年血脂异常领域的最新指南更新和十大关键研究,重点介绍了脂质降脂治疗的突破与临床应用。

“钙化零分”不是安全绿灯:丹麦超2万人研究揭示,LDL-C升高仍会显著增加年轻人心血管风险

这项大型研究得出一个关键结论:冠状动脉钙化积分为零并不等于心血管绝对安全。

AHA 2025:美国成年人载脂蛋白B与低密度脂蛋白胆固醇不一致现象及其临床意义

本研究揭示美国成年人ApoB与LDL-C水平不一致的高发率,强调两者联合检测对指导降脂治疗的重要性。

警惕!中国孩子吃多支链氨基酸或升血脂,每多1克异亮氨酸,高 LDL-C 风险增 30%

本研究基于中国儿童青少年群体,揭示膳食支链氨基酸(BCAAs)摄入量与高低密度脂蛋白胆固醇(LDL-C)升高的显著正相关关系,提示合理控制BCAAs摄入有助于预防心血管疾病。